What is Relmada Therapeutics, Inc.'s new issues (in shares)?

Relmada Therapeutics, Inc. (RLMD) reported new issues (in shares) of 29.5M in Q1 2026.

Relmada Therapeutics, Inc. RLMD New issues (in shares)

Trilogy MetalsTMQ

174.4K—

Diversified Energy DEC

8.5M—

ATN InternationalATNI

181.5K+2.7%

Evommune EVMN

220M—

PopularBPOP

15.3K-22.5%

EyePoint, Inc. EYPT

2.2M—

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Operating cash flow-$15.1M+16.6%

Market cap$677.17M+2,907%

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockIssuedDuringPeriodSharesNewIssues.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Relmada Therapeutics, Inc.'s new issues (in shares)?: Relmada Therapeutics, Inc. (RLMD) reported new issues (in shares) of 29.5M in Q1 2026.